Cited 0 times in
Subcutaneous Interleukin-2 Monotherapy for Metastatic Renal Cell Carcinoma in Korean Patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최영득 | - |
dc.date.accessioned | 2022-05-09T16:50:30Z | - |
dc.date.available | 2022-05-09T16:50:30Z | - |
dc.date.issued | 2021-11 | - |
dc.identifier.issn | 2234-4977 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/188234 | - |
dc.description.abstract | Purpose This study was a prospective single-arm clinical trial aimed at assessing the efficacy and toxicity of subcutaneous interleukin (IL)-2 monotherapy in patients with metastatic renal cell carcinoma (RCC). Materials and Methods We enrolled 26 patients with metastatic RCC in this multicenter con-trolled trial. The patients received subcutaneous injections of recombinant IL-2 (BMI-rh-IL2, an aldesleukin biosimilar, BMIKOREA Co., Ltd.) in 5-week cycles. In the first week, the patients received a subcutaneous IL-2 loading dose of 18×106 IU once on treatment days 1–5, followed by 2 days of rest. In the following 3 weeks, they received a dose of 18×106 IU via subcutaneous injection once on treatment days 1 and 2. Then, the patients received a dose of 9×106 IU via subcutaneous injection once on treatment days 3, 4, and 5, followed by 2 days of rest. The pri-mary end point was the objective response rate; the secondary end points were progression-free survival (PFS) and safety. Results Overall, 22 patients were included in the final per-protocol analysis. The objective response and the disease control rates were 13.64% (3 of 22), and 90.9% (20 of 22), respectively. The mean PFS was 5.55 months (95% confidence interval, 2.71–8.4). The proportion of patients who experienced a treatment-related grade 3 or 4 adverse event was 3.85% (1 of 26). There were no treatment-related deaths. Conclusions In this study, the subcutaneous IL-2 monotherapy regimen demonstrated ef-ficacy and safety comparable to those reported in previous studies of subcutaneous IL-2 mono-therapy and was effective in Korean patients with metastatic RCC. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | Korean Journal of Urological Oncology | - |
dc.publisher | Korean Journal of Urological Oncology | - |
dc.relation.isPartOf | Korean Journal of Urological Oncology | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Subcutaneous Interleukin-2 Monotherapy for Metastatic Renal Cell Carcinoma in Korean Patients | - |
dc.title.alternative | Subcutaneous Interleukin-2 Monotherapy for Metastatic Renal Cell Carcinoma in Korean Patients | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Urology (비뇨의학교실) | - |
dc.contributor.googleauthor | Jeong Ho Kim | - |
dc.contributor.googleauthor | Ki Soo Lee | - |
dc.contributor.googleauthor | Choung-Soo Kim | - |
dc.contributor.googleauthor | Young Deuk Choi | - |
dc.contributor.googleauthor | Tae Hyo Kim | - |
dc.identifier.doi | 10.22465/kjuo.2021.19.4.252 | - |
dc.contributor.localId | A04111 | - |
dc.relation.journalcode | J02133 | - |
dc.identifier.eissn | 2233-5633 | - |
dc.subject.keyword | Renal cell carcinoma | - |
dc.subject.keyword | Interleukin-2 | - |
dc.subject.keyword | Clinical trial | - |
dc.subject.keyword | Metastasis | - |
dc.subject.keyword | Subcutaneous injections | - |
dc.contributor.alternativeName | Choi, Young Deuk | - |
dc.contributor.affiliatedAuthor | 최영득 | - |
dc.citation.volume | 19 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 252 | - |
dc.citation.endPage | 260 | - |
dc.identifier.bibliographicCitation | Korean Journal of Urological Oncology, Vol.19(4) : 252-260, 2021-11 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.